Welcome to our dedicated page for ORASURE TECHNOLOGIES SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OraSure Technologies Inc. filings document the regulatory record of a Nasdaq-listed diagnostics and sample management company. Its Form 8-K reports cover quarterly and annual operating results, Regulation FD presentations, business developments, board changes, and material agreements tied to shareholder and governance matters.
OraSure's proxy materials disclose director elections, executive compensation, board committee structure, shareholder voting matters and governance proposals, including matters related to board classification. The filings also identify the company's common stock listing, capital structure, risk and governance disclosures, and formal records for cooperation agreements, director appointments, resignations and investor communications.
Marmora Lelio reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Lelio Marmora received a grant of 46,106 shares of Common Stock as a stock award, not through an open-market purchase. The shares were granted at no cash cost as part of the OraSure Technologies, Inc. Stock Award Plan.
The restricted shares will vest in full on the earlier of June 3, 2027, or immediately before the start of the company’s 2027 Annual Meeting of Stockholders, provided Marmora continues to serve on the board. Vesting stops immediately if he voluntarily leaves the board. After this grant, he directly holds 148,460 shares.
Kenny John P. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John P. Kenny received a grant of 46,106 shares of Common Stock as a stock award. The grant was made at a price of $0.00 per share, increasing his direct holdings to 209,714 shares after the transaction.
According to the award terms, these restricted shares will vest in full on the earlier of June 3, 2027 or immediately before the start of the company’s 2027 Annual Meeting of Stockholders. Vesting will stop immediately if he voluntarily leaves the Board before that time.
Bertrand John D. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John D. Bertrand received a grant of 46,106 shares of Common Stock as an equity award. The shares are restricted and were granted at no cash cost to him.
The award vests in full on the earlier of June 3, 2027 or immediately before the company’s 2027 Annual Meeting of Stockholders, provided he continues serving on the Board. Vesting stops if he voluntarily leaves the Board, meaning unvested shares would not be earned. After this grant, he directly holds 79,767 OraSure shares.
Boyd Steven Kyle reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Steven Kyle Boyd received a grant of 46,106 shares of common stock as a restricted stock award. The shares were granted at no cash cost to him and are part of the OraSure Technologies, Inc. Stock Award Plan.
These restricted shares will vest in full on the earlier of June 3, 2027, or immediately before the start of the company’s 2027 Annual Meeting of Stockholders, as long as he continues to serve on the Board. If he voluntarily leaves the Board before that time, vesting stops immediately. After this grant, Boyd directly holds 159,568 OraSure shares.
OraSure Technologies, Inc. held its 2026 annual stockholder meeting, where stockholders approved an amendment and restatement of the 2000 Stock Award Plan to add authorization for 5,000,000 additional shares of common stock for awards. Stockholders also approved an amendment to the Certificate of Incorporation to declassify the board of directors over three years beginning with the fiscal 2027 annual meeting, so directors standing for election then and thereafter will serve one-year terms.
All three Class II director nominees were elected, Grant Thornton LLP was ratified as independent auditor for 2026, and the advisory vote on executive compensation passed. As of the April 10, 2026 record date, there were 71,965,612 shares of common stock outstanding.
OraSure Technologies Inc. director Steven Kyle Boyd reported a series of open-market purchases of the company’s Common Stock. Over three days, he bought a total of 75,000 shares at prices between $2.98 and $3.02 per share. Following these transactions, he directly owned 113,462 shares.
Bertrand John D. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John D. Bertrand received a grant of 33,661 shares of common stock as an equity award. The shares were granted at no cash cost to him and are structured as restricted stock. They cliff vest on May 12, 2028, meaning the entire award vests at once on that date if he continues serving on the Board. Vesting stops immediately if he voluntarily leaves the Board before that date.
OraSure Technologies director John D. Bertrand submitted a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing is administrative in nature and, in the data provided, does not report any share purchases, sales, or option exercises.
OraSure Technologies director Lelio Marmora reported a routine share disposition related to taxes, not an open-market trade. On the vesting of restricted shares, 28,406 common shares were withheld at $3.02 per share to cover associated tax liabilities.
After this tax-withholding disposition, Marmora directly holds 102,354 shares of OraSure Technologies common stock. This type of transaction is compensation-related and does not represent a discretionary purchase or sale in the open market.
OraSure Technologies director Robert W. McMahon reported a tax-withholding disposition of 22,888 shares of Common Stock at $3.02 per share. These shares were withheld to cover taxes due on the vesting of restricted shares, and McMahon now directly holds 77,031 shares.